Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
Tweet
Share
E-mailGet Alerts AXSM Hot Sheet
Price: $214.69 +0.47%
Rating Summary:
26 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
26 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles C. Duncan reiterated an Overweight rating and $153.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
The analyst commented, "We slightly reduced our projected revenue ramp for Sunosi, which slightly decreased our 2025/2026 EPS estimates. There is no change to our OW rating and $153 PT."
For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.
Shares of Axsome Therapeutics closed at $116.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
- Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cantor Fitzgerald, Charles Duncan, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
